OBJECTIVE: To identify correlates of spontaneous hepatitis C virus (HCV) clearance among people with human immunodeficiency virus (HIV) co-infection. DESIGN: Baseline (2001-2004) analysis of a cohort study of people with hemophilia. METHODS: Detailed questionnaire data were used to identify dates of primary HCV and HIV infections and to categorize sex; race; alcohol use; interferon treatment; hepatitis B virus (HBV) status; and HIV/AIDS history, treatment and current status. Spontaneous HCV clearance was defined as nondetection of HCV RNA by polymerase chain reaction assay in paired annual plasma, excluding those treated with interferon. Chi-squared, Fisher exact test, and logistic regression were used to identify correlates of clearance. RESULTS: Among 478 HIV-infected participants, 61 (12.8%) had cleared HCV. Among the 31 participants with chronic HBV (as well as HIV), 16 (51.6%) had cleared HCV. With chronic HBV, HCV clearance was increased 11.2-fold (95% confidence interval, 5.1-24.8), after adjusting for sex, race, and hemophilia severity. Excluding the participants with chronic HBV, the prevalence of HCV clearance was 10.1%; and it was significantly reduced among males (9.7%, P = 0.05), blacks (1.6%, P = 0.01), and participants with severe hemophilia (8.2%, P = 0.02). HCV clearance was not associated with HIV RNA detection in plasma, CD4 cell count, anti-HIV therapy, AIDS history, ages at or years of HIV or HCV infection, or alcohol consumption. CONCLUSIONS: HCV clearance is unambiguously and markedly increased with chronic HBV infection among HIV co-infected people.
OBJECTIVE: To identify correlates of spontaneous hepatitis C virus (HCV) clearance among people with human immunodeficiency virus (HIV) co-infection. DESIGN: Baseline (2001-2004) analysis of a cohort study of people with hemophilia. METHODS: Detailed questionnaire data were used to identify dates of primary HCV and HIV infections and to categorize sex; race; alcohol use; interferon treatment; hepatitis B virus (HBV) status; and HIV/AIDS history, treatment and current status. Spontaneous HCV clearance was defined as nondetection of HCV RNA by polymerase chain reaction assay in paired annual plasma, excluding those treated with interferon. Chi-squared, Fisher exact test, and logistic regression were used to identify correlates of clearance. RESULTS: Among 478 HIV-infectedparticipants, 61 (12.8%) had cleared HCV. Among the 31 participants with chronic HBV (as well as HIV), 16 (51.6%) had cleared HCV. With chronic HBV, HCV clearance was increased 11.2-fold (95% confidence interval, 5.1-24.8), after adjusting for sex, race, and hemophilia severity. Excluding the participants with chronic HBV, the prevalence of HCV clearance was 10.1%; and it was significantly reduced among males (9.7%, P = 0.05), blacks (1.6%, P = 0.01), and participants with severe hemophilia (8.2%, P = 0.02). HCV clearance was not associated with HIV RNA detection in plasma, CD4 cell count, anti-HIV therapy, AIDS history, ages at or years of HIV or HCV infection, or alcohol consumption. CONCLUSIONS:HCV clearance is unambiguously and markedly increased with chronic HBV infection among HIV co-infected people.
Authors: Jason Grebely; Maria Prins; Margaret Hellard; Andrea L Cox; William O Osburn; Georg Lauer; Kimberly Page; Andrew R Lloyd; Gregory J Dore Journal: Lancet Infect Dis Date: 2012-05 Impact factor: 25.071
Authors: Monika Sarkar; Peter Bacchetti; Phyllis Tien; Elizabeth Mileti; Audrey L French; Brian R Edlin; Marla Keller; Eric Seaberg; Marek J Nowicki; Mary Young; Marion G Peters Journal: Dig Dis Sci Date: 2012-11-24 Impact factor: 3.199
Authors: Charlotte H B S van den Berg; Bart P X Grady; Janke Schinkel; Thijs van de Laar; Richard Molenkamp; Robin van Houdt; Roel A Coutinho; Debbie van Baarle; Maria Prins Journal: PLoS One Date: 2011-11-15 Impact factor: 3.240
Authors: Andrea D Branch; Mark L Van Natta; Marie-Louise Vachon; Douglas T Dieterich; Curtis L Meinert; Douglas A Jabs Journal: Clin Infect Dis Date: 2012-04-24 Impact factor: 9.079
Authors: Gerlinde R Van de Walle; Troels K H Scheel; Joy E Tomlinson; Raphael Wolfisberg; Ulrik Fahnøe; Roosheel S Patel; Sheetal Trivedi; Arvind Kumar; Himanshu Sharma; Louise Nielsen; Sean P McDonough; Jens Bukh; Bud C Tennant; Amit Kapoor; Brad R Rosenberg; Charles M Rice; Thomas J Divers Journal: Hepatology Date: 2021-06-11 Impact factor: 17.298